Julian Baker’s Carisma Therapeutics CARM Stock Holding History

Julian Baker’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-131,221	Closed	-$5.12M	–	101
2018 Q2	$5.12M	Buy	+131,221	New	+$5.78M	0.04%	74

Other funds holding CARM

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

CHP

Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Julian Baker's CARM Position: Q3 2018 in Review

Julian Baker sold out of Carisma Therapeutics (CARM) in Q3 2018, closing a stake of 131,221 shares — an estimated $5.12M sold.

Julian Baker first reported a position in CARM in Q2 2018 and held it in 1 quarter. The position peaked at $5.12M in Q2 2018. 47 funds tracked by Wall St. Rank hold CARM as of Q3 2018.

Julian Baker reported no remaining Carisma Therapeutics position as of Q3 2018 after selling out during the quarter.
Julian Baker sold 131,221 Carisma Therapeutics shares in Q3 2018, an estimated $5.12M.
Julian Baker first reported a position in Carisma Therapeutics in Q2 2018 and held it in 1 quarter.
Julian Baker's Carisma Therapeutics position peaked at $5.12M in Q2 2018.
47 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2018.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.